1. AB0377 Switching from bio-original etanercept to biosimilar etanercept sb4: patient acceptability and outcomes in the real world. (15th June 2017) Authors: Holroyd, C; Wallis, D; Bennett, S; Clayton, P; Edwards, CJ Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dose reduction of biological therapies for inflammatory rheumatic diseases: what do patients think?. (4th May 2019) Authors: Wallis, D; Holmes, C; Holroyd, C; Sonpal, K; Zarroug, J; Adams, J; Edwards, CJ Journal: Scandinavian journal of rheumatology Issue: Volume 48:Number 3(2019) Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0426 High levels of employment but persisting work place impairment in patients with axial spondyloarthritis on biologic therapy. (15th June 2017) Authors: Nadin, TG; Wallis, D; Holroyd, C; Clayton, P; Armstrong, R; Cooper, C; Davidson, B; Harvey, N; Dennison, E; Seth, R; Walker-Bone, KE; Bennett, S; Edwards, CJ Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 933 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗